Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe carried out an option exercise and share sale on April 6, 2026. Okupe exercised options to acquire 3,975 shares of Class A Common Stock at an exercise price of $5.01 per share, for a total exercise cost of $19,914. The same day he sold 3,975 Class A shares for aggregate proceeds of approximately $79,408, with execution prices ranging between $19.95 and $20.02 per share.
The pair of transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that the CFO adopted on May 21, 2025. After recording these moves, Okupe holds 318,789 shares of Hims & Hers Class A Common Stock directly, and has an indirect stake of 7,853 shares held in the Oluyemi Okupe Separate Property Trust.
Separately, corporate disclosures show additional planned insider activity: Okupe filed to sell 240,560 shares, valued at roughly $4.9 million, through Goldman Sachs & Co. LLC.
These insider transactions occurred amid a significant business update for Hims & Hers. The company announced a partnership with Novo Nordisk to provide FDA-approved GLP-1 medications to its customer base. The offering will include Wegovy in both injection and pill forms as well as Ozempic injection pens for the treatment of Type 2 diabetes. Hims & Hers has set a subscription fee of $149 per month for its GLP-1 service, a price point that the company notes is slightly above that of competitor Ro.
Market reaction to the Novo Nordisk partnership has been pronounced: Hims & Hers shares have posted a substantial rally, described by the company as the stock's best week on record. Analysts have taken note of the momentum while expressing differing views on valuation; BofA Securities is maintaining a Neutral rating on the company with a price target of $23.
The convergence of insider option activity, the CFO's planned larger share sale filing, the commercial tie-up with a major pharmaceutical company, and an analyst stance of neutrality combine to produce a period of heightened attention for Hims & Hers from investors and market watchers.
Context and chronology
- April 6, 2026: Okupe exercised 3,975 options at $5.01 per share and sold 3,975 Class A shares at prices between $19.95 and $20.02, netting about $79,408 from the sale.
- May 21, 2025: Date the CFO's Rule 10b5-1 trading plan was adopted, under which the April 6 trades were executed.
- Company announcement: New distribution arrangement with Novo Nordisk to offer Wegovy (injection and pill forms) and Ozempic injection pens for Type 2 diabetes; GLP-1 subscription fee set at $149 per month.
- Analyst note: BofA Securities retains a Neutral rating, $23 price target.
What this means for market participants
Investors and analysts are digesting concurrent signals: insider option activity and sales recorded by the CFO, a sizable planned sale filing, and a strategic commercial partnership that has coincided with a marked upward move in the company's share price.